---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001577"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2023-03-10T23:59:59+00:00"
generated_at: "2026-06-18T05:14:26.355112+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Harvard Bioscience approves 2023 cash incentive plan for CEO and Interim CFO

## Summary
- Compensation Committee approved 2023 annual cash incentive plan on March 6, 2023.
- CEO and Interim CFO receive target award as a percentage of 2023 base salary.
- Payout can range from 0% to 150% of target based on corporate financial objectives.
- No specific targets, dollar amounts, or performance thresholds disclosed.

## SEC filing metadata
- accession: 0001171843-23-001577
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2023-03-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184323001577/0001171843-23-001577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184323001577/f8k_031023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001577
- JSON: https://secwatch.observer/filing/0001171843-23-001577.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001577.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.